- Home
- EDF vs KRRO Comparison
EDF vs KRRO Comparison
Compare EDF & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- KRRO
- Stock Information
- Founded
- EDF 2010
- KRRO 2014
- Country
- EDF United States
- KRRO United States
- Employees
- EDF N/A
- KRRO N/A
- Industry
- EDF Investment Managers
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- KRRO Health Care
- Exchange
- EDF Nasdaq
- KRRO Nasdaq
- Market Cap
- EDF 160.2M
- KRRO 147.4M
- IPO Year
- EDF N/A
- KRRO 2019
- Fundamental
- Price
- EDF $5.05
- KRRO $33.22
- Analyst Decision
- EDF
- KRRO Strong Buy
- Analyst Count
- EDF 0
- KRRO 7
- Target Price
- EDF N/A
- KRRO $96.71
- AVG Volume (30 Days)
- EDF 160.6K
- KRRO 237.0K
- Earning Date
- EDF 01-01-0001
- KRRO 11-11-2025
- Dividend Yield
- EDF 13.14%
- KRRO N/A
- EPS Growth
- EDF N/A
- KRRO N/A
- EPS
- EDF N/A
- KRRO N/A
- Revenue
- EDF N/A
- KRRO $6,281,000.00
- Revenue This Year
- EDF N/A
- KRRO $97.27
- Revenue Next Year
- EDF N/A
- KRRO N/A
- P/E Ratio
- EDF N/A
- KRRO N/A
- Revenue Growth
- EDF N/A
- KRRO N/A
- 52 Week Low
- EDF $3.51
- KRRO $10.29
- 52 Week High
- EDF $5.50
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- EDF 44.55
- KRRO 67.72
- Support Level
- EDF $4.97
- KRRO $30.36
- Resistance Level
- EDF $5.09
- KRRO $37.03
- Average True Range (ATR)
- EDF 0.06
- KRRO 3.68
- MACD
- EDF -0.01
- KRRO -0.07
- Stochastic Oscillator
- EDF 34.78
- KRRO 77.36
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.